You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.
Cities and start-ups are pushing to incorporate SARS-CoV-2 wastewater monitoring into pandemic responses even as basic science researchers scramble to hammer out methods.
The company expects to garner clearance for its platform in the US first for Lynch syndrome as it builds additional evidence for an immunotherapy application.
Promega will seek to expand use of the assay in Europe while it works through regulatory review of the test for companion diagnostic use in the US and Asia.
Co-Diagnostics' test, which recently received Emergency Use Authorization in the US, is designed to detect the RdRp gene of the SARS-CoV-2 virus.
The companies have signed on to a new public-private initiative organized by Wisconsin's governor intended to increase the state's testing capacity.
Promega said it plans to use the technology to create new research products for investigating endogenous biology.
Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.
Verogen's ForenSeq kit and Thermo Fisher Scientific's Precision ID Whole Genome Panel can now be used to create DNA profiles for a national repository.
The test uses multiplex PCR fragment analysis with Promega-designed five-mononucleotide repeat markers to detect the MSI-high phenotype within tumor tissues.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.